A new study of secukinumab (Cosentyx) found changes from baseline in patient global assessment of disease activity among those taking secukinumab were more than twice as high compared to those receiving placebo. “Further studies should address predictors of good patient-reported outcome response to treatment in psoriatic arthritis,” the study authors concluded.

Click here for more.